Monaco Asset Management SAM Sells 536,288 Shares of Ventyx Biosciences, Inc. $VTYX

Monaco Asset Management SAM lessened its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 70.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 225,603 shares of the company’s stock after selling 536,288 shares during the quarter. Monaco Asset Management SAM owned 0.32% of Ventyx Biosciences worth $702,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Hudson Bay Capital Management LP bought a new position in Ventyx Biosciences in the 2nd quarter valued at about $34,000. Engineers Gate Manager LP bought a new position in shares of Ventyx Biosciences in the second quarter valued at approximately $42,000. Persistent Asset Partners Ltd purchased a new position in shares of Ventyx Biosciences during the third quarter valued at approximately $51,000. Jump Financial LLC bought a new stake in Ventyx Biosciences during the second quarter worth $53,000. Finally, Jane Street Group LLC bought a new stake in Ventyx Biosciences during the first quarter worth $56,000. 97.88% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on VTYX. Oppenheimer cut Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 8th. Piper Sandler downgraded shares of Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 target price for the company. in a report on Thursday, January 8th. UBS Group restated a “neutral” rating and set a $14.00 price target (down from $20.00) on shares of Ventyx Biosciences in a report on Thursday, January 8th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $14.00 target price on shares of Ventyx Biosciences in a report on Thursday, January 8th. Finally, Canaccord Genuity Group lowered Ventyx Biosciences from a “buy” rating to a “hold” rating and dropped their price target for the stock from $16.00 to $14.00 in a report on Thursday, January 8th. Eight analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $14.00.

Insiders Place Their Bets

In other news, insider John Nuss sold 12,675 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the completion of the transaction, the insider directly owned 489,481 shares in the company, valued at approximately $3,778,793.32. This trade represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Raju Mohan sold 47,345 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $365,503.40. Following the sale, the chief executive officer directly owned 2,372,863 shares in the company, valued at $18,318,502.36. This trade represents a 1.96% decrease in their position. The disclosure for this sale is available in the SEC filing. 14.49% of the stock is owned by company insiders.

Ventyx Biosciences Stock Up 0.1%

Ventyx Biosciences stock opened at $13.97 on Friday. The firm has a 50 day moving average price of $12.17 and a 200-day moving average price of $7.63. Ventyx Biosciences, Inc. has a twelve month low of $0.78 and a twelve month high of $25.00. The company has a market capitalization of $1.00 billion, a P/E ratio of -9.31 and a beta of 1.25.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.